ISG15 and ovarian cancer: These data indicated that only ISG15 downregulation may not be enough to induce cisplatin resistance, but its downregulation might be implicated in maintenance of CSC‐like features and make a significant contribution to cisplatin resistance of ovarian cancer cells.